There is no link between GLP-1 medications and suicidal thoughts, according to the European Medicines Agency.
The EU regulator began reviewing the drugs after patients in Iceland taking GLP-1 drugs reported thoughts of suicide and self-harm. The agency said it had collected around 150 cases of reports of self-injury or suicidal thoughts.
According to a April 12 news release, the agency reviewed evidence from non-clinical studies, clinical trials, post-marketing surveillance data and published studies and concluded there is no causal link between the drugs and suicidal thoughts or actions. The European Medicines Agency reviewed five different types of GLP-1 drugs, including semaglutide, the active ingredient in diabetes treatment Ozempic and its weight loss formulation Wegovy.
In January, the FDA said early investigations did not find a causal link between GLP-1 drugs and suicidal thoughts. A study published in Nature in January found patients taking GLP-1 drugs had slightly lower rates of suicidal ideation than patients taking other forms of weight loss drugs.